Share
Sandi See Tai
Sandi See Tai, MD, has been promoted to Chief Development Officer...
Lexeo Therapeutics Appoints New Executives and Board Member
Lexeo Therapeutics, Inc has strengthened its leadership team with several key executive appointments to drive the company’s pipeline into late-stage clinical development.
With nearly 20 years of industry experience, Dr. See Tai previously held leadership roles at Pfizer, where she spearheaded the late-stage clinical development of tafamidis for ATTR cardiomyopathy, resulting in global regulatory approvals.
